A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05538130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called "BRAF V600" * received required prior treatment for cancer per cohort assigned. All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day. Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.
Study identification
- NCT ID
- NCT05538130
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 148 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2022 (Actual)
- Primary completion
- Aug 31, 2027 (Estimated)
- Completion
- Aug 31, 2027 (Estimated)
- Last update posted
- Sep 1, 2026
2022 – 2027
United States locations
- U.S. sites
- 44
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Kirklin Clinic of UAB Hospital | Birmingham | Alabama | 35233 | — |
| The University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| University of Alabama at Birmingham - Phase I Clinical Trials Unit | Birmingham | Alabama | 35249 | — |
| Highlands Oncology Group, PA | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology Group, PA | Rogers | Arkansas | 72758 | — |
| Highlands Oncology Group, PA | Springdale | Arkansas | 72762 | — |
| The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate | Los Angeles | California | 90025 | — |
| Keck Hospital of USC | Los Angeles | California | 90033 | — |
| Los Angeles General Medical Center | Los Angeles | California | 90033 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Keck Medical Center of USC Pasadena | Pasadena | California | 91105 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| UCSF Helen Diller Medical Center at Parnassus Heights | San Francisco | California | 94143 | — |
| UCSF Medical Center, Investigational Pharmacy | San Francisco | California | 94158 | — |
| The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only) | Santa Monica | California | 90404 | — |
| Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center | Tampa | Florida | 33612 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Moffitt McKinley Hospital | Tampa | Florida | 33612 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Brigitte Harris Cancer Pavilion | Detroit | Michigan | 48202 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| MSK Basking Ridge. | Basking Ridge | New Jersey | 07920 | — |
| MSK Monmouth. | Middletown | New Jersey | 07748 | — |
| MSK Bergen. | Montvale | New Jersey | 07645 | — |
| MSK Commack. | Commack | New York | 11725 | — |
| MSK Westchester. | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center 53rd street. | New York | New York | 10022 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Columbia University Medical Center - Neurological Institute of New York | New York | New York | 10032 | — |
| CUIMC Research Pharmacy | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | 10065 | — |
| MSK Nassau. | Uniondale | New York | 11553 | — |
| Cleveland Clinic Taussig Cancer Center Investigational Pharmacy | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| Providence Cancer Institute Franz Clinic | Portland | Oregon | 97213 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison | Wisconsin | 53718 | — |
| University of Wisconsin Carbone Cancer Center - University Hospital | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05538130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05538130 live on ClinicalTrials.gov.